Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has received reimbursement approval in France for its Xience V Everolimus Eluting Coronary Stent System, the first drug eluting stent to demonstrate clinical superiority over another drug eluting stent in a randomized clinical trial.
Subscribe to our email newsletter
The French Health Authority (Haute Autorite de Sante) granted Xience V an ASA Level IV medical benefit rating (Amelioration du Service Attendu) on recognizing the superior clinical results for Xience V compared to the Taxus paclitaxel-eluting coronary stent system in the SPIRIT II and III randomized clinical trials. This distinction recognizes an improved medical benefit for Xience V compared to Taxus. Abbott’s Xience V drug eluting stent will become available to all public and private hospitals throughout France in February.
John Capek, executive vice president, Medical Devices, Abbott, said: “Abbott looks forward to introducing Xience V as a new standard of care in the treatment of coronary artery disease to physicians and patients in France.”